Point72 Asset Management
CTNM

Point72 Asset Management’s Contineum Therapeutics CTNM Stock Holding History

Point72 Asset Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.11M Sell
84,891
-674,336
-89% -$9.04M ﹤0.01% 2707
2025
Q4 		$8.68M Buy
759,227
+391,582
+107% +$4.47M 0.01% 1445
2025
Q3 		$4.32M Sell
367,645
-20,994
-5% -$169K 0.01% 1121
2025
Q2 		$1.54M Buy
+388,639
New +$1.69M ﹤0.01% 1410

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management's CTNM Position: Q1 2026 in Review

Point72 Asset Management reduced its Contineum Therapeutics (CTNM) stake by 89% in Q1 2026, selling an estimated $9.04M and leaving 84,891 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2707.

Point72 Asset Management first reported a position in CTNM in Q2 2025 and has held it in 4 quarters since. The position peaked at $8.68M in Q4 2025. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Point72 Asset Management held 84,891 shares of Contineum Therapeutics worth $1.11M as of Q1 2026.
  • Point72 Asset Management sold 674,336 Contineum Therapeutics shares in Q1 2026, an estimated $9.04M.
  • Contineum Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2707 holding.
  • Point72 Asset Management first reported a position in Contineum Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Point72 Asset Management's Contineum Therapeutics position peaked at $8.68M in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.